βhCG as a prognostic marker in adenocarcinoma of the prostate

Journal of Clinical Pathology

Volumn 49, Issue 4, 1996, Pages 329-332

  Sheaff, M T ^a   Martin, J E ^a   Badenoch, D F ^b   Baithun, S I ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b Department of Urology ^*

Author keywords

Adenocarcinoma; Prognosis; Prostate; human chorionic gonadotrophin

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA;

EID: 0029916435     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.4.329     Document Type: Article

References (25)

1. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic and therapeutic implications. Cancer 1992;70(Suppl):254-68.
2. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone and serotonin immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
3. Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994; 18:1240-6.
4. Fetissof F, Bruandet P, Arbeille B, Penot J, Marboeuf Y, Le-Roux J, et al. Calcitonin-secreting carcinomas of the prostate. An immunohistochemical and ultrastructural analysis. Am J Surg Pathol 1986;10:702-10.
5. Jenkins BJ, Martin JE, Baithun SI, Zuk RJ, Oliver RTD, Blandy JP. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol 1990;65:345-8.
6. Martin JE, Jenkins BJ, Zuk RJ, Blandy JP, Baithun SI. Human chorionic gonadotrphin expression and histological findings as predictors of response to radiotherapy in carcinomas of the bladder. Virchows Arch A Pathol Anat Histopathol 1989;414:273-7.
7. Iles RK, Chard T. Human chorionic gonadotrophin expression in bladder cancers: biology and clinical potential. J Urol 1991;145:453-8.
8. Campo E, Palacin A, Benasco C, Quesada E, Cardesa A. Human chorionic gonadotrophin in colorectal carcinoma, an immunohistochemical study. Cancer 1985;59:1611-16.
9. Kiernan M, Gaffney EF. The endocrine-paracrine cells of von Brunn's nests and glandular metaplasia in the supramontanal prostatic urethra. Histopathology 1990;16: 365-9.
10. McManus LM, Naughton MA, Martinez-Hernandez A. Human chorionic gonadotrophin in human neoplastic cells. Cancer Res 1976;36:3476-81.
11. Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F. Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 1977;40:211-16.
12. Papapetrou PD, Sakarelou NP, Braouzi H, Fessas PH. Ectopic production of human chorionic gonadotrophin (hCG) by neoplasms: The value of measurements of immunoreactive hCG in the urine as a screening procedure. Cancer 1980;45:2583-92.
13. Fukutani K, Libby JM, Panko WB, Scardino PT. Human chorionic gonadotrophin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol 1983;129:74-7.
14. Purnell DM, Heatfield BM, Trump BF. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, β-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res 1984;44:285-92.
15. Shah VM, Newman J, Crocker J, Antonakopoulos GN, Chapple CR, Collard MJ. Production of β-human chorionic gonadotrophin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. Br J Exp Pathol 1987;68:871-8.
16. Oliver RT, Stephenson C, Collino CE, Parkinson MC. Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer. Molecular Biotherapy 1988;1:43-5.
17. Grigor KM. Germ cell tumours of the testis. In: Anthony PP, MacSween RNM, eds. Recent advances in histopathology. Vol 15. Edinburgh: Churchill Livingstone, 1992:177-94.
18. Daehlin L. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic cancer. Scand J Urol Nephrol Suppl 1985; 91:1-44.
19. Daehlin L, Damber JE, Selstam G, Bergman B. Effects of human chorionic gonadotrophin, oestradiol and estromustine on testicular blood flow in hypophysectomized rats. Int J Androl 1985;8:58-68.
20. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hseih JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
21. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118:616-18.
22. Fox SB, Persad SA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erb-B2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 1994;74:214-20.
23. Kokuko M, Yoshiki T, Hameguchi A, Okada Y, Tomoyoshi T, Higuchi K. Immunohistochemical study of c-erb B2 proto-oncogene product in prostatic cancer. Nippon Hinyokika Gakkai Zasshi 1993;84:1872-8.
24. Beastall GH, Cook B, Rustin GJ, Jennings J. A review of established tumour markers. Ann Clin Biochem 1991;28: 5-18.
25. Yamanaka N, Kawabata G, Morisue K, Hazama M, Nishimura R. Urinary hCG beta-core fragment as a tumor marker for bladder cancer. Nippon Hinyokika Gakkai Zasshi 1993;84:700-6